2013
DOI: 10.1007/s13238-013-3051-8
|View full text |Cite
|
Sign up to set email alerts
|

Inflammasomes in cancer: a double-edged sword

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
53
0
4

Year Published

2015
2015
2022
2022

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 41 publications
(58 citation statements)
references
References 90 publications
1
53
0
4
Order By: Relevance
“…20 In the current study, γ-PGA showed antiinflammasome activity, which increases its potential as a promising target for cancer therapy and metabolic diseases. 13,14 Indeed, treatments targeting IL-1β (IL-1 receptor antagonist or IL-1β monoclonal antibodies), caspase-1 inhibitors or inflammasome inhibitors have been shown to control inflammasome-mediated diseases. 15,30 However, these diseases require continuous treatment because their symptoms manifest slowly, which furthers the physical and economic burden for patients.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…20 In the current study, γ-PGA showed antiinflammasome activity, which increases its potential as a promising target for cancer therapy and metabolic diseases. 13,14 Indeed, treatments targeting IL-1β (IL-1 receptor antagonist or IL-1β monoclonal antibodies), caspase-1 inhibitors or inflammasome inhibitors have been shown to control inflammasome-mediated diseases. 15,30 However, these diseases require continuous treatment because their symptoms manifest slowly, which furthers the physical and economic burden for patients.…”
Section: Discussionmentioning
confidence: 99%
“…13 Collectively, inflammasomes have received increased attention as new therapeutic targets of tumors and metabolic disorders. 14,15 In this study, we investigated the effects of γ-PGA on inflammasome activation. γ-PGA attenuated IL-1β and IL-18 secretion, which are readouts of inflammasome activation, in the presence of NLRP3, NLRC4 and AIM2 triggers.…”
Section: Introductionmentioning
confidence: 99%
“…However, excessive or inappropriate activation of NLRP3 inflammasome is implicated in the pathogenesis of inherited and acquired inflammatory diseases, leading to increased inflammatory responses in lung metastases and suppression of antitumor immunity in certain conditions . The NLRP3 inflammasome also plays an important role in the development and progression of gastrointestinal cancer, skin cancer, breast cancer and hepatocellular carcinoma . Furthermore, the over‐expressed and constitutively activated NLRP3 inflammasome contributes to the progression of late‐stage melanoma, whereas it is considerably down‐regulated in human hepatocellular carcinoma …”
Section: Nlrp3 Inflammasome and Tumorigenesismentioning
confidence: 99%
“…Mounting evidence indicates that NLRP3 inflammasome plays an important role in the development and progression of gastrointestinal cancer, skin cancer, breast cancer and hepatocellular carcinoma (7). However, the effects of NLRP3 inflammasome on the progression of various cancers are complex.…”
Section: Introductionmentioning
confidence: 99%